BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 23725390)

  • 1. Clinical significance of down-regulated cylindromatosis gene in chronic lymphocytic leukemia.
    Wu W; Zhu H; Fu Y; Shen W; Xu J; Miao K; Hong M; Xu W; Liu P; Li J
    Leuk Lymphoma; 2014 Mar; 55(3):588-94. PubMed ID: 23725390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High LEF1 expression predicts adverse prognosis in chronic lymphocytic leukemia and may be targeted by ethacrynic acid.
    Wu W; Zhu H; Fu Y; Shen W; Miao K; Hong M; Xu W; Fan L; Young KH; Liu P; Li J
    Oncotarget; 2016 Apr; 7(16):21631-43. PubMed ID: 26950276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NDRG2 mRNA levels and miR-28-5p and miR-650 activity in chronic lymphocytic leukemia.
    Yang YQ; Tian T; Zhu HY; Liang JH; Wu W; Wu JZ; Xia Y; Wang L; Fan L; Li JY; Xu W
    BMC Cancer; 2018 Oct; 18(1):1009. PubMed ID: 30348117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IGHV3-21 gene usage is associated with high TCL1 expression in chronic lymphocytic leukemia.
    Mansouri MR; Sevov M; Aleskog A; Jondal M; Merup M; Sundström C; Osorio L; Rosenquist R
    Eur J Haematol; 2010 Feb; 84(2):109-16. PubMed ID: 19889012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of LPL gene expression in patients with chronic lymphocytic leukemia.
    Bilous N; Abramenko I; Chumak A; Dyagil I; Martina Z
    Exp Oncol; 2019 Mar; 41(1):39-45. PubMed ID: 30932419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia.
    Karan-Djurasevic T; Palibrk V; Kostic T; Spasovski V; Nikcevic G; Srzentic S; Colovic M; Colovic N; Vidovic A; Antic D; Mihaljevic B; Pavlovic S; Tosic N
    Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):252-60. PubMed ID: 22560084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum tumor necrosis factor-α and interleukin-10 levels as markers to predict outcome of patients with chronic lymphocytic leukemia in different risk groups defined by the IGHV mutation status.
    Lech-Maranda E; Grzybowska-Izydorczyk O; Wyka K; Mlynarski W; Borowiec M; Antosik K; Cebula-Obrzut B; Makuch-Lasica H; Nowak G; Klimkiewicz-Wojciechowska G; Wawrzyniak E; Bilinski P; Robak T; Warzocha K
    Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):477-86. PubMed ID: 22945689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated miR-20b-5p expression in peripheral blood mononuclear cells: A novel, independent molecular biomarker of favorable prognosis in chronic lymphocytic leukemia.
    Papageorgiou SG; Kontos CK; Tsiakanikas P; Stavroulaki G; Bouchla A; Vasilatou D; Bazani E; Lazarakou A; Scorilas A; Pappa V
    Leuk Res; 2018 Jul; 70():1-7. PubMed ID: 29715621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LPL gene expression is associated with poor prognosis in CLL and closely related to NOTCH1 mutations.
    Kristensen L; Kristensen T; Abildgaard N; Royo C; Frederiksen M; Mourits-Andersen T; Campo E; Møller MB
    Eur J Haematol; 2016 Aug; 97(2):175-82. PubMed ID: 26558352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dysregulation of TNFα-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1.
    Liu P; Xu B; Shen W; Zhu H; Wu W; Fu Y; Chen H; Dong H; Zhu Y; Miao K; Xu W; Li J
    Leukemia; 2012 Jun; 26(6):1293-300. PubMed ID: 22157808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia.
    Nückel H; Collins CH; Frey UH; Sellmann L; Dürig J; Siffert W; Dührsen U
    Eur J Haematol; 2009 Dec; 83(6):541-9. PubMed ID: 19682311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZAP-70 mRNA quantification in B-cell chronic lymphocytic leukaemia.
    Catherwood MA; Matthews C; Niblock R; Dobbin E; Morris TC; Alexander HD
    Eur J Haematol; 2006 Apr; 76(4):294-8. PubMed ID: 16519700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
    Le Bris Y; Struski S; Guièze R; Rouvellat C; Prade N; Troussard X; Tournilhac O; Béné MC; Delabesse E; Ysebaert L
    Hematol Oncol; 2017 Dec; 35(4):664-670. PubMed ID: 27678008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions.
    Patten PE; Chu CC; Albesiano E; Damle RN; Yan XJ; Kim D; Zhang L; Magli AR; Barrientos J; Kolitz JE; Allen SL; Rai KR; Roa S; Mongini PK; MacCarthy T; Scharff MD; Chiorazzi N
    Blood; 2012 Dec; 120(24):4802-11. PubMed ID: 23071276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IGHV3-21 gene expression in patients with B-cell chronic lymphocytic leukemia in Ukraine.
    Abramenko I; Bilous N; Kryachok I; Filonenko I; Pilipenko G; Chumak A; Bazyka D; Bebeshko V
    Exp Oncol; 2007 Sep; 29(3):226-30. PubMed ID: 18004251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis.
    Del Giudice I; Chiaretti S; Santangelo S; Tavolaro S; Peragine N; Marinelli M; Ilari C; Raponi S; Messina M; Nanni M; Mauro FR; Piciocchi A; Bontempi K; Rossi D; Gaidano G; Guarini A; Foà R
    Am J Hematol; 2014 Jan; 89(1):74-82. PubMed ID: 24030933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials.
    Wojdacz TK; Amarasinghe HE; Kadalayil L; Beattie A; Forster J; Blakemore SJ; Parker H; Bryant D; Larrayoz M; Clifford R; Robbe P; Davis ZA; Else M; Howard DR; Stamatopoulos B; Steele AJ; Rosenquist R; Collins A; Pettitt AR; Hillmen P; Plass C; Schuh A; Catovsky D; Oscier DG; Rose-Zerilli MJJ; Oakes CC; Strefford JC
    Blood Adv; 2019 Aug; 3(16):2474-2481. PubMed ID: 31434681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia.
    Joshi AD; Hegde GV; Dickinson JD; Mittal AK; Lynch JC; Eudy JD; Armitage JO; Bierman PJ; Bociek RG; Devetten MP; Vose JM; Joshi SS
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5295-304. PubMed ID: 17875758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients.
    Duzkale H; Schweighofer CD; Coombes KR; Barron LL; Ferrajoli A; O'Brien S; Wierda WG; Pfeifer J; Majewski T; Czerniak BA; Jorgensen JL; Medeiros LJ; Freireich EJ; Keating MJ; Abruzzo LV
    Blood; 2011 Apr; 117(15):4076-84. PubMed ID: 21310924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia.
    Raval A; Lucas DM; Matkovic JJ; Bennett KL; Liyanarachchi S; Young DC; Rassenti L; Kipps TJ; Grever MR; Byrd JC; Plass C
    J Clin Oncol; 2005 Jun; 23(17):3877-85. PubMed ID: 15809452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.